Changes of biochemical parameters of psoriasis metabolic syndrome patients before and after the treatment with the inhibitor of TNF

doi:10.3969/j.issn.1673-8640.2019.06.011

Abstract

Abstract:

Objective To compare the biochemical parameters of psoriasis patients before and after tumor necrosis factor（TNF） inhibitor treatment,and to investigate the possible mechanism of anti-TNF antibody in reducing the risk of metabolic syndrome among psoriasis patients. Methods A retrospective cohort study of psoriasis patients treated with anti-TNF antibody was conducted. A total of 203 psoriasis patients were matched by sex,age,disease duration and PASI score,and 200 healthy subjects were enrolled as healthy control group. Totally,21 biochemical parameters were compared between healthy control group and psoriasis group before and after treatment. Results The levels of high-density lipoprotein cholesterol（HDL-C） and apolipoprotein A（apo A） in psoriasis group were lower than those in healthy control group before treatment（P<0.05）,and the levels were close to those in healthy control group after TNF inhibitor treatment. There was no statistical significance for the other parameters between healthy control group and psoriasis group before and after treatment（P>0.05）. Conclusions Anti-TNF antibody can improve the biochemical parameters related to psoriasis metabolic syndrome. It provides a reference for the treatment of metabolic syndrome caused by psoriasis and the pathogenesis of psoriasis metabolic syndrome.

Key words: Psoriasis, Tumor necrosis factor inhibitor cholesterol, High-density lipoprotein cholesterol, Apolipoprotein A

CLC Number:

R446.1

CHANG Jinghua, WANG Jianbiao. Changes of biochemical parameters of psoriasis metabolic syndrome patients before and after the treatment with the inhibitor of TNF[J]. Laboratory Medicine, 2019, 34(6): 530-533.

Figures/Tables 1

References 10

[1]	WU J J,TSAI T F.Recurrent hyperglycemia during adalimumab treatment in a patient with psoriasis[J]. Arch Dermatol,2008,144(10):1403-1404.
[2]	MANOLIS A A,MANOLIS T A,MELITA H,et al.Psoriasis and cardiovascular disease:the elusive link[J]. Int Rev Immunol,2019,38(1):1-22.
[3]	CHARYTAN D M,SOLOMON S D,IVANOVICH P,et al.Metformin use and cardiovascular events in patients with type 2 diabetes and chronic kidney disease[J]. Diabetes Obes Metab,2019,21(5):1199-1208.
[4]	SOUBRIER M,JOUANEL P,MATHIEU S,et al.Effects of anti-tumor necrosis factor therapy on lipid profile in patients with rheumatoid arthritis[J]. Joint Bone Spine,2008,75(1):22-24.
[5]	WANG X,SHI N,SHI H,et al.Correlations of acute cerebral hemorrhage complicated with stress ulcer bleeding with acute physiology and chronic health evaluation(APACHE) Ⅱ score,endothelin(ET),tumor necrosis factor-alpha(TNF-α),and blood lipids[J]. Med Sci Monit,2018,24:9120-9126.
[6]	GONZALEZ-JUANATEY C,TESTA A,GARCIA-CASTELO A,et al.Active but transient improvement of endothelial function in rheumatoid arthritis patients undergoing long-term treatment with anti-tumor necrosis factor alpha antibody[J]. Arthritis Rheum,2004,51(3):447-450.
[7]	ARICAN O,ARAL M,SASMAZ S,et al.Serum levels of TNF-alpha,IFN-gamma,IL-6,IL-8,IL-12,IL-17,and IL-18 in patients with active psoriasis and correlation with disease severity[J]. Mediators Inflamm,2005,2005(5):273-279.
[8]	RONDINONE C M.Adipocyte-derived hormones,cytokines,and mediators[J]. Endocrine,2006,29(1):81-90.
[9]	PÉREZ L,VALLEJOS A,ECHEVERRIA C,et al. OxHDL controls LOX-1 expression and plasma membrane localization through a mechanism dependent on NOX/ROS/NF-κB pathway on endothelial cells[J]. Lab Invest,2019,99(3):421-437.
[10]	MA G,BI S.Effect of rosuvastatin on vascular endothelial functions and inflammatory factors of patients with type 2 diabetes mellitus and coronary heart disease[J]. Exp Ther Med,2019,17(1):332-336.

组别	例数	FFA（mmol/L）	TC（mmol/L）	TG（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
银屑病组	203
治疗前		0.53（0.22~0.84）	4.99±0.97	1.72（1.01~2.11）	1.08±0.27*#	3.07±0.85
治疗后		0.58（0.26~0.79）	5.03±0.98	1.69（1.22~1.98）	1.27±0.28	3.11±0.81
正常对照组	200	0.55（0.24~0.81）	5.13±0.91	1.72（1.25~2.06）	1.28±0.29	3.12±0.79
P值		0.30	0.37	0.19	0.02	0.54
组别		ALP（IU/L）	apo A（g/L）	apo B（g/L）	apo E（g/L）	Lp（a）（g/L）
银屑病组
治疗前		66（58~67）	1.18（1.09~1.72）*#	1.00±0.34	1.02±0.01	0.24±0.02
治疗后		68（56~71）	1.40（1.01~1.69）	0.98±0.22	0.98±0.01	0.21±0.03
正常对照组		67（56~68）	1.39（1.12~1.70）	0.96±0.28	0.95±0.01	0.23±0.03
P值		0.08	0.03	0.22	0.13	0.61
组别		Glu（mmol/L）	TP（g/L）	PA（mg/L）	DBil（μmol/L）	TB（μmol/L）
银屑病组
治疗前		6.14±1.80	73.28±3.86	273.33（227.04~308.17）	2.77（1.71~2.95）	15.64±3.59
治疗后		6.22±1.45	72.46±3.45	271.73（231.04~301.25）	2.74（1.70~2.97）	15.29±3.82
正常对照组		6.21±1.47	72.59±3.35	274.93（229.18~297.64）	2.73（1.69~2.96）	15.39±3.62
P值		0.27	0.11	0.21	0.66	0.34
组别		钾（mmol/L）	钠（mmol/L）	氯（mmol/L）	磷（mmol/L）	镁（mmol/L）
银屑病组
治疗前		4.24±0.28	142.75±2.07	103.83±1.83	1.05±0.13	0.90±0.06
治疗后		4.37±0.33	142.68±1.78	104.50±2.18	1.00±0.16	0.87±0.06
正常对照组		4.35±0.31	141.69±1.79	103.52±2.08	1.01±0.15	0.86±0.05
P值		0.13	0.91	0.31	0.31	0.15

组别	例数	FFA（mmol/L）	TC（mmol/L）	TG（mmol/L）	HDL-C（mmol/L）	LDL-C（mmol/L）
银屑病组	203
治疗前		0.53（0.22~0.84）	4.99±0.97	1.72（1.01~2.11）	1.08±0.27*#	3.07±0.85
治疗后		0.58（0.26~0.79）	5.03±0.98	1.69（1.22~1.98）	1.27±0.28	3.11±0.81
正常对照组	200	0.55（0.24~0.81）	5.13±0.91	1.72（1.25~2.06）	1.28±0.29	3.12±0.79
P值		0.30	0.37	0.19	0.02	0.54
组别		ALP（IU/L）	apo A（g/L）	apo B（g/L）	apo E（g/L）	Lp（a）（g/L）
银屑病组
治疗前		66（58~67）	1.18（1.09~1.72）*#	1.00±0.34	1.02±0.01	0.24±0.02
治疗后		68（56~71）	1.40（1.01~1.69）	0.98±0.22	0.98±0.01	0.21±0.03
正常对照组		67（56~68）	1.39（1.12~1.70）	0.96±0.28	0.95±0.01	0.23±0.03
P值		0.08	0.03	0.22	0.13	0.61
组别		Glu（mmol/L）	TP（g/L）	PA（mg/L）	DBil（μmol/L）	TB（μmol/L）
银屑病组
治疗前		6.14±1.80	73.28±3.86	273.33（227.04~308.17）	2.77（1.71~2.95）	15.64±3.59
治疗后		6.22±1.45	72.46±3.45	271.73（231.04~301.25）	2.74（1.70~2.97）	15.29±3.82
正常对照组		6.21±1.47	72.59±3.35	274.93（229.18~297.64）	2.73（1.69~2.96）	15.39±3.62
P值		0.27	0.11	0.21	0.66	0.34
组别		钾（mmol/L）	钠（mmol/L）	氯（mmol/L）	磷（mmol/L）	镁（mmol/L）
银屑病组
治疗前		4.24±0.28	142.75±2.07	103.83±1.83	1.05±0.13	0.90±0.06
治疗后		4.37±0.33	142.68±1.78	104.50±2.18	1.00±0.16	0.87±0.06
正常对照组		4.35±0.31	141.69±1.79	103.52±2.08	1.01±0.15	0.86±0.05
P值		0.13	0.91	0.31	0.31	0.15